Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation
- PMID: 19187764
- PMCID: PMC2715556
- DOI: 10.1016/j.molcel.2008.12.026
Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation
Abstract
The LKB1-AMPK signaling pathway serves as a critical cellular sensor coupling energy homeostasis to cell growth, proliferation, and survival. However, how tumor cells suppress this signaling pathway to gain growth advantage under conditions of energy stress is largely unknown. Here, we show that AMPK activation is suppressed in melanoma cells with the B-RAF V600E mutation and that downregulation of B-RAF signaling activates AMPK. We find that in these cells LKB1 is phosphorylated by ERK and Rsk, two kinases downstream of B-RAF, and that this phosphorylation compromises the ability of LKB1 to bind and activate AMPK. Furthermore, expression of a phosphorylation-deficient mutant of LKB1 allows activation of AMPK and inhibits melanoma cell proliferation and anchorage-independent cell growth. Our findings provide a molecular linkage between the LKB1-AMPK and the RAF-MEK-ERK pathways and suggest that suppression of LKB1 function by B-RAF V600E plays an important role in B-RAF V600E-driven tumorigenesis.
Figures
Similar articles
-
Uncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAF.PLoS One. 2009;4(3):e4771. doi: 10.1371/journal.pone.0004771. Epub 2009 Mar 10. PLoS One. 2009. PMID: 19274086 Free PMC article.
-
B-Raf(V600E) signaling deregulates the mitotic spindle checkpoint through stabilizing Mps1 levels in melanoma cells.Oncogene. 2008 May 15;27(22):3122-33. doi: 10.1038/sj.onc.1210972. Epub 2007 Dec 10. Oncogene. 2008. PMID: 18071315
-
ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.Mol Cancer. 2017 Jun 8;16(1):102. doi: 10.1186/s12943-017-0667-y. Mol Cancer. 2017. PMID: 28595656 Free PMC article.
-
Controlling the master-upstream regulation of the tumor suppressor LKB1.Oncogene. 2018 Jun;37(23):3045-3057. doi: 10.1038/s41388-018-0145-z. Epub 2018 Mar 15. Oncogene. 2018. PMID: 29540834 Review.
-
Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.Pharmacol Res. 2018 Sep;135:239-258. doi: 10.1016/j.phrs.2018.08.013. Epub 2018 Aug 15. Pharmacol Res. 2018. PMID: 30118796 Review.
Cited by
-
The Role of Autophagy in Human Uveal Melanoma and the Development of Potential Disease Biomarkers and Novel Therapeutic Paradigms.Biomedicines. 2024 Feb 19;12(2):462. doi: 10.3390/biomedicines12020462. Biomedicines. 2024. PMID: 38398064 Free PMC article. Review.
-
Metabolic Profiling to Assess Response to Targeted and Immune Therapy in Melanoma.Int J Mol Sci. 2024 Jan 31;25(3):1725. doi: 10.3390/ijms25031725. Int J Mol Sci. 2024. PMID: 38339003 Free PMC article. Review.
-
cAMP-PKA/EPAC signaling and cancer: the interplay in tumor microenvironment.J Hematol Oncol. 2024 Jan 17;17(1):5. doi: 10.1186/s13045-024-01524-x. J Hematol Oncol. 2024. PMID: 38233872 Free PMC article. Review.
-
Josephin domain containing 2 (JOSD2) promotes lung cancer by inhibiting LKB1 (Liver kinase B1) activity.Signal Transduct Target Ther. 2024 Jan 5;9(1):11. doi: 10.1038/s41392-023-01706-y. Signal Transduct Target Ther. 2024. PMID: 38177135 Free PMC article.
-
Characterization of dabrafenib-induced drug insensitivity via cellular barcoding and collateral sensitivity to second-line therapeutics.Sci Rep. 2024 Jan 2;14(1):286. doi: 10.1038/s41598-023-50443-3. Sci Rep. 2024. PMID: 38167959 Free PMC article.
References
-
- Alessi DR, Sakamoto K, Bayascas JR. LKB1-dependent signaling pathways. Annu Rev Biochem. 2006;75:137–163. - PubMed
-
- Asara JM, Christofk HR, Freimark LM, Cantley LC. A label-free quantification method by MS/MS TIC compared to SILAC and spectral counting in a proteomics screen. Proteomics. 2008;8:994–999. - PubMed
-
- Ashrafian H. Cancer's sweet tooth: the Janus effect of glucose metabolism in tumorigenesis. Lancet. 2006;367:618–621. - PubMed
-
- Baas AF, Kuipers J, van der Wel NN, Batlle E, Koerten HK, Peters PJ, Clevers HC. Complete polarization of single intestinal epithelial cells upon activation of LKB1 by STRAD. Cell. 2004;116:457–466. - PubMed
-
- Bardeesy N, Sinha M, Hezel AF, Signoretti S, Hathaway NA, Sharpless NE, Loda M, Carrasco DR, DePinho RA. Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature. 2002;419:162–167. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- K99CA133245/CA/NCI NIH HHS/United States
- K99 CA133245/CA/NCI NIH HHS/United States
- P01 CA120964/CA/NCI NIH HHS/United States
- CA102694/CA/NCI NIH HHS/United States
- K99 CA133245-01/CA/NCI NIH HHS/United States
- U01 CA084313/CA/NCI NIH HHS/United States
- R01 CA093947/CA/NCI NIH HHS/United States
- U01 CA84313/CA/NCI NIH HHS/United States
- R01 CA093947-08/CA/NCI NIH HHS/United States
- R01 GM056203-12/GM/NIGMS NIH HHS/United States
- R01 CA93947/CA/NCI NIH HHS/United States
- GM56203/GM/NIGMS NIH HHS/United States
- P01 CA120964-01A10002/CA/NCI NIH HHS/United States
- R01 GM056203/GM/NIGMS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
